MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.73
+0.61
+1.40%
Opening 11:22 08/12 EDT
OPEN
43.52
PREV CLOSE
43.12
HIGH
44.11
LOW
43.06
VOLUME
43.23K
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
33.80
MARKET CAP
598.38M
P/E (TTM)
271.08
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EGRX stock price target is 49.33 with a high estimate of 57.00 and a low estimate of 45.00.

EPS

EGRX News

More
Eagle Pharmaceuticals Inc (EGRX) Q2 2020 Earnings Call Transcript
At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' Second Quarter 2020 Earnings Results Conference Call. It's now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. This is Lisa Wilson, Inve
Motley Fool · 1d ago
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
Eagle Pharmaceuticals Q2 EPS $0.57 Beats $0.26 Estimate, Sales $41.90M Miss $42.28M Estimate
Eagle Pharmaceuticals (NASDAQ:EGRX) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.26 by 119.23 percent. This is a 32.14 percent decrease over earnings of $0.84 per share
Benzinga · 2d ago
Eagle Pharmaceuticals Reports Second Quarter 2020 Results
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced financial results for the three and six months ended June 30, 2020.
Business Wire · 2d ago
Eagle Pharmaceuticals to Discuss Second Quarter 2020 Financial Results on August 10, 2020
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2020 second quarter financial results on Monday, August 10, 2020, before the market opens.
Business Wire · 08/03 20:30
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
July turned out to be a mixed month for FDA approvals. Endo International PLC's (NASDAQ: ENDP) cellulite treatment, Osmotica Pharmaceuticals PLC's (NASDAQ: OSMT) eye disorder drug and Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ) drug to treat excessive daytime sl
Benzinga · 07/31 19:56
CMS Establishes Unique J-Code for Eagle Pharmaceuticals’ PEMFEXY™ (Pemetrexed for Injection)
Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code for PEMFEXY™ (pemetrexed for injection). This new Healthcare C
Business Wire · 07/09 16:00
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. 
Benzinga · 07/06 12:56

Industry

Pharmaceuticals
+1.96%
Pharmaceuticals & Medical Research
+1.54%

Hot Stocks

Symbol
Price
%Change

About EGRX

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
More

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.